Value doesn't come from the effort you put in. I'm sorry. It doesn't. It doesn't come from struggle, or your sweat, or your tears. It doesn't come from your experiences. It doesn't come from how many hours you worked at it or how many years you took to learn to do it. Those things may help you to put a price tag on what you need to compensate you - but that's not the same thing at all. You can dig holes and fill them in again all day long, but all that effort isn't going to result in anything valuable. It comes purely and only from the demand anyone else has for it, which is often just something very subjective and irrational which you have no control over. Someone dying in a desert values that bottle of water far more than the Mona Lisa. The labour theory of value as an argument for "real art" is as wrong as it is for anything else. Meaning is individual, personal, relative and subjective. Someone using AI as part of their workflow to produce something successful, instead of some other tool, has no bearing on the output People can produce slop with pen & paper, and other people will produce art with AI. The fact that the artist was able to possibly work faster or iterate on concepts faster has no bearing on their aesthetics and taste, which is what creates something the demand for their work. If people are producing crap with it, I doubt they'd have done any better using any other medium

Microsoft AI CEO Mustafa Suleyman: the social contract for content that is on the open web is that it's "freeware" for training AI models

It is false to suggest—as some recently have—that our patents are being used to prevent access to SIRTURO® (bedaquiline), our medicine for MDR-TB. In fact, we have already entered into a collaboration with the Stop TB Partnership’s Global Drug Facility (“GDF”)—the largest procurer of TB medicines—which enables them to invite potential generic suppliers and purchase generic versions of SIRTURO® 100mg. On April 5, during a World Health Organization meeting, the GDF shared its intent to launch a tender for generic versions of SIRTURO® 100mg in the third quarter of 2023: social.jnj.com/3XSgjRZ In addition, we have shipped more than 660,000 courses of SIRTURO® to 159 countries since launch. Our patents made this possible, enabling us to assist countries to scale-up their use of our medicine responsibly and sustainably and invest in multiple, critical, anti-TB efforts. For instance, in the face of rising drug resistance, we support stewardship efforts that ensure MDR-TB patients can benefit from our medicine today and in the future. Unfortunately, the most significant barrier to treatment access for patients today is the fact that millions of patients with TB go undiagnosed every year. This is a challenge that we have invested significant resources to overcome and must all get behind if we are to achieve the global goal of ending TB.